Hyperion DeFi (HYPD) Competitors $6.16 +0.06 (+0.98%) As of 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock HYPD vs. NVCT, BIOA, GLSI, CRDF, DERM, CLLS, MEIP, ELDN, BDTX, and LXEOShould you be buying Hyperion DeFi stock or one of its competitors? The main competitors of Hyperion DeFi include Nuvectis Pharma (NVCT), BioAge Labs (BIOA), Greenwich LifeSciences (GLSI), Cardiff Oncology (CRDF), Journey Medical (DERM), Cellectis (CLLS), MEI Pharma (MEIP), Eledon Pharmaceuticals (ELDN), Black Diamond Therapeutics (BDTX), and Lexeo Therapeutics (LXEO). These companies are all part of the "pharmaceutical products" industry. Hyperion DeFi vs. Its Competitors Nuvectis Pharma BioAge Labs Greenwich LifeSciences Cardiff Oncology Journey Medical Cellectis MEI Pharma Eledon Pharmaceuticals Black Diamond Therapeutics Lexeo Therapeutics Nuvectis Pharma (NASDAQ:NVCT) and Hyperion DeFi (NASDAQ:HYPD) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their dividends, media sentiment, risk, institutional ownership, analyst recommendations, earnings, valuation and profitability. Which has more risk & volatility, NVCT or HYPD? Nuvectis Pharma has a beta of -0.26, meaning that its share price is 126% less volatile than the S&P 500. Comparatively, Hyperion DeFi has a beta of 2.42, meaning that its share price is 142% more volatile than the S&P 500. Do analysts rate NVCT or HYPD? Nuvectis Pharma currently has a consensus target price of $15.33, indicating a potential upside of 123.19%. Hyperion DeFi has a consensus target price of $2.00, indicating a potential downside of 67.53%. Given Nuvectis Pharma's stronger consensus rating and higher probable upside, equities analysts plainly believe Nuvectis Pharma is more favorable than Hyperion DeFi.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Nuvectis Pharma 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00Hyperion DeFi 0 Sell rating(s) 4 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 Is NVCT or HYPD more profitable? Nuvectis Pharma has a net margin of 0.00% compared to Hyperion DeFi's net margin of -62,238.41%. Nuvectis Pharma's return on equity of -150.81% beat Hyperion DeFi's return on equity.Company Net Margins Return on Equity Return on Assets Nuvectis PharmaN/A -150.81% -94.84% Hyperion DeFi -62,238.41%-876.25%-181.67% Do insiders & institutionals have more ownership in NVCT or HYPD? 96.8% of Nuvectis Pharma shares are held by institutional investors. Comparatively, 25.8% of Hyperion DeFi shares are held by institutional investors. 30.5% of Nuvectis Pharma shares are held by company insiders. Comparatively, 10.9% of Hyperion DeFi shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth. Does the media prefer NVCT or HYPD? In the previous week, Nuvectis Pharma had 4 more articles in the media than Hyperion DeFi. MarketBeat recorded 5 mentions for Nuvectis Pharma and 1 mentions for Hyperion DeFi. Nuvectis Pharma's average media sentiment score of 1.16 beat Hyperion DeFi's score of 0.21 indicating that Nuvectis Pharma is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Nuvectis Pharma 3 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Hyperion DeFi 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Which has better valuation & earnings, NVCT or HYPD? Nuvectis Pharma has higher earnings, but lower revenue than Hyperion DeFi. Nuvectis Pharma is trading at a lower price-to-earnings ratio than Hyperion DeFi, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioNuvectis PharmaN/AN/A-$19M-$1.17-5.87Hyperion DeFi$60K584.17-$49.82M-$58.40-0.11 SummaryNuvectis Pharma beats Hyperion DeFi on 12 of the 15 factors compared between the two stocks. Get Hyperion DeFi News Delivered to You Automatically Sign up to receive the latest news and ratings for HYPD and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding HYPD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart HYPD vs. The Competition Export to ExcelMetricHyperion DeFiBiotechnology IndustryMedical SectorNASDAQ ExchangeMarket Cap$35.05M$137.09M$5.82B$9.74BDividend YieldN/A3.74%3.84%4.09%P/E Ratio-0.113.8731.1525.97Price / Sales584.174,053.59475.57123.18Price / CashN/A13.1937.1558.38Price / Book0.9446.309.116.39Net Income-$49.82M-$90.99M$3.26B$265.66M7 Day Performance-14.44%0.61%2.11%1.98%1 Month Performance-46.53%3.58%5.12%1.33%1 Year Performance-85.91%197.78%31.25%21.15% Hyperion DeFi Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)HYPDHyperion DeFi0.3011 of 5 stars$6.16+1.0%$2.00-67.5%-83.6%$35.05M$60K-0.1140Gap DownNVCTNuvectis Pharma3.8378 of 5 stars$6.45+0.3%$15.33+137.7%-11.3%$163.69MN/A-5.518Positive NewsBIOABioAge LabsN/A$4.52-0.7%N/AN/A$163.12M$3.86M0.00N/AGLSIGreenwich LifeSciences1.4633 of 5 stars$12.01-1.3%$39.00+224.7%-19.9%$162.69MN/A-8.833Trending NewsAnalyst ForecastAnalyst RevisionCRDFCardiff Oncology1.6497 of 5 stars$2.43-0.4%$10.10+315.6%-3.0%$162.32M$680K-2.7920DERMJourney Medical1.6736 of 5 stars$7.00+0.7%$10.83+54.8%+60.9%$161.91M$56.13M-18.4290CLLSCellectis3.3874 of 5 stars$2.90+1.8%$4.00+37.9%+17.6%$158.41M$49.22M-3.54290Positive NewsShort Interest ↓MEIPMEI Pharma1.3625 of 5 stars$4.88-0.2%N/A+47.1%$158.28M$65.30M-1.03100ELDNEledon Pharmaceuticals1.7387 of 5 stars$2.60-1.1%$10.00+284.6%-10.8%$157.49MN/A-2.2210Short Interest ↑BDTXBlack Diamond Therapeutics3.2618 of 5 stars$2.75-0.4%$12.40+350.9%-58.5%$157.14MN/A11.9690Positive NewsLXEOLexeo Therapeutics2.4216 of 5 stars$4.92+4.2%$15.33+211.7%-62.3%$156.69M$650K-1.5158Analyst Revision Related Companies and Tools Related Companies NVCT Competitors BIOA Competitors GLSI Competitors CRDF Competitors DERM Competitors CLLS Competitors MEIP Competitors ELDN Competitors BDTX Competitors LXEO Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:HYPD) was last updated on 8/22/2025 by MarketBeat.com Staff From Our PartnersEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredElon Musk’s New TechnologyElon Musk is building something in Memphis that could eclipse even Tesla and SpaceX. At the heart of it is a n...Paradigm Press | SponsoredNew law could create $3.7 trillion tsunami.During a meeting in Washington D.C., Jeff Brown discovered a bold initiative. He calls it “President Trump’...Brownstone Research | SponsoredA grave, grave error.Nvidia just shattered records—hitting $4 trillion in valuation faster than any company in history. But one ...Porter & Company | SponsoredThe Tiny Stock Set to Soar with Musk's AI AmbitionsThe Tiny Stock Set to Soar with Musk's AI Ambitions While Musk builds one of the most ambitious AI empires ...Behind the Markets | SponsoredTake a look at this picture ...A strange investment secret — discovered just a few short weeks before this image was taken — correctly predic...Weiss Ratings | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Hyperion DeFi, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Hyperion DeFi With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access